Publicado 4 números por año
ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448
Indexed in
Iron, Erythropoietic Stimulating Agents, and Anemia in Cancer
SINOPSIS
Anemia commonly accompanies malignancies in patients and may contribute to morbidity. Correction of the anemia with erythropoietic stimulating agents, while possible, may be associated with complications such as tumor progression and adverse cardiovascular events. This review examines the data behind these concerns and raises the strategy of using iron, alone, in the setting of cancer-associated anemia to reduce exposure to transfusions in these patients and to potentially improve their quality of life.
-
Beguin Yves, Aapro Matti, Ludwig Heinz, Mizzen Lee, Österborg Anders, Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis—A critical review, Critical Reviews in Oncology/Hematology, 89, 1, 2014. Crossref
-
Lang Elisabeth, Bissinger Rosi, Qadri Syed M., Lang Florian, Suicidal death of erythrocytes in cancer and its chemotherapy: A potential target in the treatment of tumor-associated anemia, International Journal of Cancer, 141, 8, 2017. Crossref
-
Li Chengyin, Zhu Fenglin, Xu Chong, Xiao Ping, Wen Junsong, Zhang Xia, Wu Bin, Dangguibuxue decoction abolishes abnormal accumulation of erythroid progenitor cells induced by melanoma, Journal of Ethnopharmacology, 242, 2019. Crossref
-
Gitlin-Domagalska Agata, Mangold Martin, Dębowski Dawid, Ptaszyńska Natalia, Łęgowska Anna, Gütschow Michael, Rolka Krzysztof, Matriptase-2: monitoring and inhibiting its proteolytic activity, Future Medicinal Chemistry, 10, 23, 2018. Crossref
-
Makharadze Tamta, Boccia Ralph, Krupa Anna, Blackman Nicole, Henry David H., Gilreath Jeffrey A., Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, p lacebo‐controlled study ( IRON ‐ CLAD ) , American Journal of Hematology, 96, 12, 2021. Crossref